<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Laronidase: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Laronidase: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Laronidase: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11178" href="/d/html/11178.html" rel="external">see "Laronidase: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13320" href="/d/html/13320.html" rel="external">see "Laronidase: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F6187724"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions including anaphylaxis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients treated with laronidase have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available during laronidase administration. If a severe hypersensitivity reaction (eg, anaphylaxis) occurs, discontinue laronidase immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reactions, a desensitization procedure to laronidase may be considered.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Acute respiratory complications associated with administration:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to infusion reactions and require additional monitoring.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F187005"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Aldurazyme</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867325"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Aldurazyme</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F187019"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Enzyme</li></ul></div>
<div class="block doa drugH1Div" id="F187006"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Appropriate medical monitoring and support measures, including CPR equipment, should be readily available during administration.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Consider premedication with antihistamines with or without antipyretic 1 hour prior to start of infusion.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="292e2029-444e-4edd-9f47-424b4bf80220">MPS I</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>MPS I (Hurler syndrome, Hurler-Scheie, and Scheie forms):</b> IV: 0.58 mg/kg once weekly; dose should be rounded up to the nearest whole vial.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose: </i>If ≥1 dose is missed, restart treatment as soon as possible, keeping the 1-week interval between infusions thereafter.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990557"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987899"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dot drugH1Div" id="F59007969"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity or infusion reaction, mild to moderate:</b> Consider temporarily holding the infusion for 15 to 30 minutes or slowing the infusion rate by 25% to 50%, and initiate appropriate medical treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If symptoms persist despite holding or slowing the infusion:</i> Discontinue the infusion and monitor the patient. Consider reinitiating the infusion within 7 to 14 days using the incremental rate steps up to 25% to 50% of the rate at which the reaction occurred; use appropriate premedication. With next infusion, increase the infusion rate by increments of 25% as tolerated until the recommended infusion rate is reached; monitor closely.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If symptoms subside after holding the infusion:</i> Resume infusion at a 25% to 50% reduced rate as tolerated. With next infusion, increase the infusion rate by increments of 25% as tolerated until the recommended infusion rate is reached; monitor closely.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>If symptoms subside after slowing the infusion:</i> Complete infusion at the reduced rate as tolerated. With next infusion, increase the infusion rate by increments of 25% as tolerated until the recommended infusion rate is reached; monitor closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity (eg, anaphylaxis) or infusion reaction, severe:</b> Discontinue immediately and initiate appropriate medical treatment. Consider risk versus benefit of readministration; may be rechallenged at slower infusion rate and desensitization may be considered. If the patient tolerates the infusion, the rate may be increased to reach the recommended rate.</p></div>
<div class="block doe drugH1Div" id="F3062777"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F187013"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13320" href="/d/html/13320.html" rel="external">see "Laronidase: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premedicate with antipyretic and/or antihistamines 1 hour prior to start of infusion.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7b7748f5-c816-44a2-b287-999efb537bbf">Mucopolysaccharidosis I</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mucopolysaccharidosis (MPS) I (Hurler syndrome, Hurler-Scheie, and Scheie phenotypes):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Enzyme replacement therapy with laronidase is typically initial therapy in Hurler-Scheie and Scheie phenotypes with initiation of treatment as early as possible to maximize long-term benefits (Al-Sannaa 2015; de Ru 2011; Horovitz 2016; Martins 2009); patients with severe Hurler syndrome at risk for neuro-cognitive impairment may be candidates for hematopoietic stem cell transplant (HSCT) with possible peri-transplant laronidase therapy; further studies needed (Parini 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weekly dosing:</i> Infants &gt;3 months, Children, and Adolescents: IV: 0.58 mg/kg/dose once weekly; dose should be rounded up to the nearest whole vial; <b>Note:</b> In FDA-approval trials, the youngest patient to receive laronidase was 6 months of age (Wraith 2007); however, sibling case-reports evaluating early laronidase therapy includes patients as young 3 to 4 months of age (Al-Sannaa 2015; Gabrielli 2010; Laraway 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Every-2-week dosing;</i> Limited data available; role in management not defined; some experts suggest regimen for patients with compliance challenges (Martins 2009); however, most data has been as maintenance therapy after 1 year of weekly dosing (Horovitz 2016; Kyosen 2019):</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥4 years and Adolescents: IV: 1.2 mg/kg/dose every other week (Giugliani 2009; Horovitz 2016; Kyosen 2019). In a trial describing use in 20 patients (median [range] age at time of extended-interval dosing for phenotype: Hurler: 6 years [3.9 to 6.2 years]; Hurler-Scheie: 12.3 years [4 to 25 years]; Scheie: 18.7 years [8 to 25 years]), data showed that patients switched to every-2-week dosing maintained existent improvement in clinical signs and laboratory parameters and no patient exhibited deterioration; therapy was reported to be well-tolerated; the range of duration of therapy reported was 1 to 9 years (Horovitz 2016).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51117813"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosing adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51117814"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosing adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F186980"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and pediatrics.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (including neutralizing antibodies)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (including pain at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, hyperreflexia, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, edema (gravitational), hypotension, increased blood pressure, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pallor, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema, severe hypersensitivity reaction (including anaphylactic shock, anaphylaxis)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Corneal opacity</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Oxygen saturation decreased, rales, respiratory distress, wheezing</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute cardiorespiratory failure, peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cyanosis, laryngeal edema</p></div>
<div class="block coi drugH1Div" id="F186992"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed within the manufacturer’s US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Severe hypersensitivity to laronidase or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F186978"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity/anaphylactoid reactions: Hypersensitivity reactions, which may include airway obstruction, bradycardia, bronchospasm, hypotension, hypoxia, respiratory distress/failure, stridor, tachypnea, and urticaria, may be severe and tend to occur during or within 3 hours after administration. In the case of anaphylaxis, caution should be used if epinephrine is being considered; many patients with MPS I have pre-existing heart disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Infusion reactions may occur; use caution and consider delaying treatment in patients with acute febrile/respiratory illness; may result in increased risk for infusion-related reactions. Pretreatment with antipyretics and antihistamines is recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid overload: Use with caution in patients at risk for fluid overload or in conditions where fluid restriction is indicated (eg, acute underlying respiratory illness, compromised cardiac and/or respiratory function); conditions may be exacerbated during infusion. Extended observation may be necessary for some patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• MPS I: Appropriate use: Has not been studied in patients with mild symptoms of the Scheie form of MPS I. Not indicated for the CNS manifestations of the disorder.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep apnea: Use with caution in patients with sleep apnea; evaluate patients prior to initiation of therapy. Apnea treatment options should be readily available (eg, CPAP or supplemental oxygen) during infusion or with use of sedating antihistamines.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Registry: A patient registry has been established and all patients are encouraged to participate. Registry information may be obtained at www.registrynxt.com or by calling 1-800-745-4447.</p></div>
<div class="block foc drugH1Div" id="F186987"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aldurazyme: 2.9 mg/5 mL (5 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F186974"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323284"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Aldurazyme Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.9 mg/5 mL (per mL): $256.93</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867326"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aldurazyme: 2.9 mg/5 mL (5 mL) [contains polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F186989"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer using an infusion set with low protein-binding and 0.2 micrometer in-line filter. Antipyretics and/or antihistamines should be administered 60 minutes prior to infusion. Volume and infusion rate are based on actual body weight; deliver infusion over ~3 to 4 hours. An initial 10 mcg/kg/hour infusion rate may be incrementally increased every 15 minutes during the first hour if tolerated (see below); increase to a maximum infusion rate of 200 mcg/kg/hour which is maintained for the remainder of the infusion (~3 hours). After administration, flush infusion line with NS at the same infusion rate as was last used for administration. Vital signs should be monitored every 15 minutes, if stable. Manufacturer provides the following infusion rate information for patients receiving usual preparation:</p>
<p style="text-indent:-2em;margin-left:4em;">≤20 kg: Total infusion volume: 100 mL.</p>
<p style="text-indent:-2em;margin-left:6em;">2 mL/hour for 15 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">4 mL/hour for 15 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">8 mL/hour for 15 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">16 mL/hour for 15 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">32 mL/hour for remainder of infusion (~3 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;20 kg: Total infusion volume: 250 mL.</p>
<p style="text-indent:-2em;margin-left:6em;">5 mL/hour for 15 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">10 mL/hour for 15 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">20 mL/hour for 15 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">40 mL/hour for 15 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">80 mL/hour for remainder of infusion (~3 hours).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Note:</b> A total infusion volume of 100 mL NS and slower infusion rate may be considered for patients with cardiac or respiratory compromise who weigh up to 30 kg.</p></div>
<div class="block admp drugH1Div" id="F52613130"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV infusion: Antipyretics and/or antihistamines should be administered 60 minutes prior to infusion. Laronidase must be diluted prior to administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Administer IV using an infusion set with low protein-binding 0.2 micrometer in-line filter. Total infusion volume and rates are based on body weight (see following table); deliver infusion over ~3 to 4 hours. For weekly administration, initiate infusion at 10 mcg/kg/hour for 15 minutes; if tolerated, the infusion rate may be incrementally increased every 15 minutes during the first hour; increase to a maximum infusion rate of 200 mcg/kg/hour which is maintained for the remainder of the infusion (approximately 3 hours). Higher doses may be administered every 2 weeks and infused over a total of 4 hours (Giugliani 2009; Kyosen 2019). If an infusion-related reaction occurs, decrease the rate of infusion, temporarily discontinue the infusion, and/or administer additional antipyretics/antihistamines.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption>
<b>Laronidase Rate Titration for Weekly or Every-2-Week<sup>a </sup> 4-hour Infusion</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Patient Weight</p></th>
<th align="center">
<p style="text-indent:0em;">Total Infusion Volume</p></th>
<th align="center">
<p style="text-indent:0em;">Volume Based Infusion Rate</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Giugliani 2009; Kyosen 2019; manufacturer's labeling</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" rowspan="5">
<p style="text-indent:0em;">≤20 kg</p></td>
<td align="center" rowspan="5">
<p style="text-indent:0em;">100 mL NS</p></td>
<td align="center">
<p style="text-indent:0em;">2 mL/hour x 15 minutes</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">4 mL/hour x 15 minutes</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">8 mL/hour x 15 minutes</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">16 mL/hour x 15 minutes</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">32 mL/hour x ~3 hours</p></td></tr>
<tr>
<td align="center" rowspan="5">
<p style="text-indent:0em;">&gt;20 kg</p></td>
<td align="center" rowspan="5">
<p style="text-indent:0em;">250 mL NS</p></td>
<td align="center">
<p style="text-indent:0em;">5 mL/hour x 15 minutes</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">10 mL/hour x 15 minutes</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">20 mL/hour x 15 minutes</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">40 mL/hour x 15 minutes</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">80 mL/hour x ~3 hours</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<b>Note: </b>For patients up to 30 kg with cardiac or respiratory compromise, a total infusion volume of 100 mL NS and slower infusion rate may be considered.</p></td></tr></tbody></table></div>
<div class="block use drugH1Div" id="F186988"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Mucopolysaccharidosis I (Hurler syndrome, Hurler-Scheie, and Scheie forms):</b> Treatment of Hurler and Hurler-Scheie forms of mucopolysaccharidosis I (MPS I) in adult and pediatric patients; treatment of Scheie form of MPS I in patients with moderate to severe symptoms.</p></div>
<div class="block cyt drugH1Div" id="F13299577"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F186981"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F186994"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to the use of laronidase in pregnancy is limited (Anbu 2006; Castorina 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Pregnant patients are encouraged to enroll in the mucopolysaccharidosis I registry (1-800-745-4447, extension 15500 or www.registrynxt.com).</p></div>
<div class="block brc drugH1Div" id="F20547778"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if laronidase is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Information related to the use of laronidase in breastfeeding women is limited (Castorina 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p>
<p style="text-indent:-2em;margin-left:2em;">Lactating women with mucopolysaccharidosis I (MPS I) are encouraged to enroll in the MPS I registry (1-800-745-4447, extension 15500 or www.registrynxt.com).</p></div>
<div class="block mop drugH1Div" id="F186985"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs, FVC, height, weight, range of motion, serum antibodies to alpha-L-iduronidase, urine levels of glycosaminoglycans (GAG), change in liver size; signs and symptoms of hypersensitivity or infusion reaction.</p></div>
<div class="block pha drugH1Div" id="F186977"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Laronidase is a recombinant (replacement) form of alpha-L-iduronidase derived from Chinese hamster cells. Alpha-L-iduronidase is an enzyme needed to break down endogenous glycosaminoglycans (GAGs) within lysosomes. A deficiency of alpha-L-iduronidase leads to an accumulation of GAGs, causing cellular, tissue, and organ dysfunction as seen in MPS I. Improved pulmonary function and walking capacity have been demonstrated with the administration of laronidase to patients with Hurler, Hurler-Scheie, or Scheie (with moderate-to-severe symptoms) forms of MPS.</p></div>
<div class="block phk drugH1Div" id="F186991"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infants and Children 6 months to 5 years: V<sub>d</sub>: 0.12-0.56 L/kg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children ≥6 years and Adults: V<sub>d</sub>: 0.24-0.6 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infants and Children 6 months to 5 years: 0.3-1.9 hours</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children ≥6 years and Adults: 1.5-3.6 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Infants and Children 6 months to 5 years: Clearance: 2.2-7.7 mL/minute/kg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children ≥6 years and Adults: Clearance: 1.7-2.7 mL/minute/kg; during the first 12 weeks of therapy the clearance of laronidase increases proportionally to the amount of antibodies a given patient develops against the enzyme. However, with long-term use (≥26 weeks) antibody titers have no effect on laronidase clearance.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038666"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Aldurasim</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aldurazyme</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aldurazyme.1">
<a name="Aldurazyme.1"></a>Aldurazyme (laronidase) [prescribing information]. Cambridge, MA: Genzyme; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aldurazyme.2">
<a name="Aldurazyme.2"></a>Aldurazyme (laronidase) [product monograph]. Toronto, Ontario, Canada: Genzyme Canada; May 2023.</div>
</li>
<li>
<div class="reference">
                  Al-Sannaa NA, Bay L, Barbouth DS, et al. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships. <i>Orphanet J Rare Dis</i>. 2015;10:131.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/26446585/pubmed" id="26446585" target="_blank">26446585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16601901">
<a name="16601901"></a>Anbu AT, Mercer J, Wraith JE. Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I. <i>J Inherit Metab Dis.</i> 2006;29(1):230-231. doi:10.1007/s10545-006-0237-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/16601901/pubmed" id="16601901" target="_blank">16601901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25864295">
<a name="25864295"></a>Castorina M, Antuzzi D, Richards SM, Cox GF, Xue Y. Successful pregnancy and breastfeeding in a woman with mucopolysaccharidosis type I while receiving laronidase enzyme replacement therapy. <i>Clin Exp Obstet Gynecol.</i> 2015;42(1):108-113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/25864295/pubmed" id="25864295" target="_blank">25864295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  de Ru MH, Boelens JJ, Das AM, et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. <i>Orphanet J Rare Dis</i>. 2011;6:55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/21831279/pubmed" id="21831279" target="_blank">21831279</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gabrielli O, Clarke LA, Bruni S, Coppa GV. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. <i>Pediatrics</i>. 2010;125(1):e183-e187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/20026495/pubmed" id="20026495" target="_blank">20026495</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Giugliani R, Rojas VM, Martins AM, et al. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. <i>Mol Genet Metab</i>. 2009;96(1):13-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/19038563/pubmed" id="19038563" target="_blank">19038563</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Horovitz DD, Acosta AX, Giugliani R, et al. Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series. <i>Orphanet J Rare Dis</i>. 2016;11(1):51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/27129473/pubmed" id="27129473" target="_blank">27129473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kyosen SO, Toma L, Nader HB, et al. Case series of patients under biweekly treatment with laronidase: a report of a single center experience. <i>Rev Paul Pediatr</i>. 2019;37(3):312-317.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/31090850/pubmed" id="31090850" target="_blank">31090850</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Laraway S, Breen C, Mercer J, Jones S, Wraith JE. Does early use of enzyme replacement therapy alter the natural history of mucopolysaccharidosis I? Experience in three siblings. <i>Mol Genet Metab</i>. 2013;109(3):315-316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/23721889/pubmed" id="23721889" target="_blank">23721889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Martins AM, Dualibi AP, Norato D, et al. Guidelines for the management of mucopolysaccharidosis type I. <i>J Pediatr</i>. 2009;155(4)(suppl):S32-S46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/19765409/pubmed" id="19765409" target="_blank">19765409</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Parini R, Deodato F, Di Rocco M, et al. Open issues in Mucopolysaccharidosis type I-Hurler. <i>Orphanet J Rare Dis</i>. 2017;12(1):112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/28619065/pubmed" id="28619065" target="_blank">28619065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17606547">
<a name="17606547"></a>Wraith JE, Beck M, Lane R, et al. Enzyme Replacement Therapy in Patients Who Have Mucopolysaccharidosis I and Are Younger Than 5 Years: Results of a Multinational Study of Recombinant Human {alpha}-L-Iduronidase (Laronidase). <i>Pediatrics</i>. 2007;120(1):e37-e46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/laronidase-drug-information/abstract-text/17606547/pubmed" id="17606547" target="_blank">17606547</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10232 Version 148.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
